摘要
目的:研究布地奈德福莫特罗粉吸入剂联合孟鲁司特对慢性阻塞性肺疾病-哮喘重叠综合征的疗效及对患者生活质量的影响。方法:选择特定研究时段(2016年12月至2017年6月)内咸宁市咸安区中医医院内科接收的66例慢阻肺联合哮喘患者,根据随机数字表法,将其分为观察组和对照组,每组各33例,对照组患者实施布地奈德福莫特罗粉吸入剂治疗,观察组患者在对照组的基础上实施孟鲁司特治疗,对比分析两种治疗方式下患者治疗有效率、治疗前后的肺功能评分以及两种治疗方式对患者生活质量的影响。结果:在与对照组进行比较之后,观察组的患者治疗率明显高于对照组,且治疗后的肺功能评分以及患者生活质量均明显优于对照组,差异具有统计学意义(P<0.05)。结论:在对慢阻肺联合哮喘患者的治疗中实施布地奈德福莫特罗粉吸入剂联合孟鲁司特效果显著,不仅可以提高患者治疗有效率,一定程度上还能改善肺功能,整体提升患者日常生活质量评分,值得广大医护工作者在临床中推广和借鉴。
Objective:To study the effect of budesonide formoterol powder inhalation combined with montelukast on chronic obstructive pulmonary disease(COPD)-asthmatic overlap syndrome(COPD)and its effect on quality of life(QOL).Methods:A total of 66 patients with COPD and asthma received in our hospital during a specific study period(December 2016 to June 2017)were randomly divided into observation group(n=33)and control group(n=33).The patients in the control group were treated with budesonide formoterol powder inhalation,and the patients in the observation group were treated with montelukast on the basis of the control group.The effect of pulmonary function score and two treatment methods on the quality of life of patients before and after treatment was studied.Results:Compared with the control group,the treatment rate of the patients in the observation group was significantly higher than that in the control group,and the pulmonary function score and the quality of life of the patients after treatment were significantly better than those in the control group(P<0.05).Conclusion:The effect of budesonide formoterol powder inhalation combined with montelukast in the treatment of patients with chronic obstructive pulmonary disease and asthma is remarkable,which can not only improve the effective rate of treatment,but also improve the pulmonary function to some extent.The overall improvement of patients'daily quality of life score is worthy of the majority of health care workers.Therefore,it should be popularized and used for reference in clinical practice.
作者
龙先勇
LONG Xian-yong(Xian'an District Hospital of Traditional Chinese Medicine,Xianning Hubei 437000,China)
出处
《药品评价》
CAS
2018年第19期51-53,共3页
Drug Evaluation